ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

23 API Suppliers, 10 USDMF, 5 EU WC, 2 KDMF, 6 NDC API, 16 Listed Suppliers

23 API Suppliers
10 USDMF
5 EU WC
2 KDMF
6 NDC API
16 Listed Suppliers

DEVELOPMENTS

7 Drugs in Development

7 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

16 FDF Dossiers, 4 FDA Orange Book, 4 Europe, 8 Canada

16 FDF Dossiers
4 FDA Orange Book
4 Europe
8 Canada

DIGITAL CONTENT

9 NEWS #PharmaBuzz

media
9 NEWS #PharmaBuzz

MARKET PLACE

1 APIs

marketPlace
1 APIs

PATENTS & EXCLUSIVITIES

28 US Patents, 14 US Exclusivities, 16 Health Canada Patents

patents
28 US Patents
14 US Exclusivities
16 Health Canada Patents

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 857890-39-2, Lenvima, Lenvatinibmesylate, Lenvatinib mesilate, Lenvatinib mesylate [usan], E7080 mesylate

Molecular Formula

C₂₂H₂₃ClN₄O₇S

Molecular Weight

523.0 g/mol

InChI Key

HWLFIUUAYLEFCT-UHFFFAOYSA-N

FDA UNII

3J78384F61

Lenvatinib Mesylate is a synthetic, orally available inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2, also known as KDR/FLK-1) tyrosine kinase with potential antineoplastic activity. E7080 blocks VEGFR2 activation by VEGF, resulting in inhibition of the VEGF receptor signal transduction pathway, decreased vascular endothelial cell migration and proliferation, and vascular endothelial cell apoptosis.

1 2D Structure

Lenvatinib Mesylate

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide;methanesulfonic acid

2.1.2 InChI

InChI=1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)

2.1.3 InChI Key

HWLFIUUAYLEFCT-UHFFFAOYSA-N

2.1.4 Canonical SMILES

COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl.CS(=O)(=O)O

2.2 Other Identifiers

2.2.1 UNII

3J78384F61

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-hydroxy-6-quinolinecarboxamide

2. 4-(3-chloro-4-((cyclopropylaminocarbonyl)amino)phenoxy)-7-methoxy-6-quinolinecarboxamide

3. 4-(3-chloro-4-(n'-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide

4. E 7080

5. E-7080

6. E-7080 Mesylate

7. E7080

8. E7080 Mesylate

9. Er-203492-00

10. Lenvatinib

11. Lenvatinib Mesilate

12. Lenvatinib Metabolite M2

13. Lenvatinib Methanesulfonate

14. Lenvima

15. N-(4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-n'-cyclopropylurea Monomethanesulfonate

2.3.2 Depositor-Supplied Synonyms

1. 857890-39-2

2. Lenvima

3. Lenvatinibmesylate

4. Lenvatinib Mesilate

5. Lenvatinib Mesylate [usan]

6. E7080 Mesylate

7. Lenvatinib (mesylate)

8. Unii-3j78384f61

9. E-7080 Mesylate

10. Chebi:85995

11. 857890-39-2 (mesylate)

12. 3j78384f61

13. Lenvatinib Mesilate (jan)

14. Lenvatinib Mesylate (usan)

15. N-(4-((6-carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-n'-cyclopropylurea Monomethanesulfonate

16. Lenvatinib Mesilate [jan]

17. 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide Mesylate

18. 4-[3-chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide;methanesulfonic Acid

19. 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide Monomethanesulfonate

20. Lenvima (tn)

21. E7080mesylate

22. E7080 (mesylate)

23. Lenvatinib Methanesulfonate

24. Lenvatinib Mesylate- Bio-x

25. Schembl865174

26. Amy385

27. Chembl2105704

28. Dtxsid90235081

29. Bcp11858

30. Hy-10981a

31. Lenvatinib Mesilate [who-dd]

32. Mfcd18633219

33. Ccg-269873

34. Sb16581

35. Lenvatinib Methanesulfonate [mi]

36. Lenvatinib Mesylate [orange Book]

37. Ac-30100

38. Bl166696

39. Ds-19245

40. Cs-0030963

41. S5240

42. D09920

43. A900902

44. Q27158839

45. 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide Methanesulfonate

46. 6-carbamoyl-4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinolin-1-ium Methanesulfonate

47. 6-quinolinecarboxamide, 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)- 7-methoxy-, Methanesulfonate (1:1)

48. 6-quinolinecarboxamide, 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)-7-methoxy-, Methanesulfonate (1:1)

49. Methanesulfonic Acid--4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide (1/1)

2.4 Create Date

2006-10-26

3 Chemical and Physical Properties

Molecular Formula	C₂₂H₂₃ClN₄O₇S
Molecular Weight	523.0 g/mol
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	8
Rotatable Bond Count	6
Exact Mass	522.0975980 g/mol
Monoisotopic Mass	522.0975980 g/mol
Topological Polar Surface Area	178 Å²
Heavy Atom Count	35
Formal Charge	0
Complexity	727
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hrthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).

Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.

5 Pharmacology and Biochemistry

5.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)

Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)

5.2 ATC Code

L01XE

API SUPPLIERS